Biotech Research & Innovation Centre BRIC, University of Copenhagen
Using a chemical systems biology approach, our group aims to functionally and therapeutically stratify cancers, to identify the underlying signals that drive them, how this relates to their molecular features and how effective personalized drug combinations can be predicted and established. To accomplish this, we use high throughput approaches to study primary and early passage cancer cells and their drug responses and relate that to their molecular characteristics. Most cancers are highly heterogeneous both on a phenotypic and genetic level and we therefore focus our studies on single cell analyses where we follow drug responses of different cancer cell subpopulations as well as how the microenvironment and the plasticity of the cells affect drug sensitivity and -resistance. Our research focus is currently on acute myeloid leukemia and high-grade serous ovarian carcinoma.